Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)

NCT06512194 is registered in ClinicalTrials.gov with Charles Raison as lead sponsor.

NCT NCT06512194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06512194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)
Lead sponsor
Charles Raison
Phase
Phase 2
Overall status
Recruiting
Start date
May 13, 2025
Completion date
May 31, 2029
Enrollment
141 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depression